Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04587388 | Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry(LUPIAE) | unknown | — | 500 | European Hematology Association - Lymphoma GroupOTHER | 6 | Oct 14, 2020 | clinicaltrials |
| NCT03380039 | Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma | unknown | N/A | 6 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER |
| 1 |
| Oct 12, 2020 |
| clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03716856 | Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma | unknown | Phase 1 | 11 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03711864 | Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma | unknown | Phase 1 | 15 | Peking Union Medical College HospitalOTHER | 1 | Sep 30, 2020 | clinicaltrials |
| NCT04447547 | Clinical Trial of SL1904B CAR-T Cells for Relapsed or Refractory Non-Hodgkin Lymphoma | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Sep 29, 2020 | clinicaltrials |
| NCT04447573 | Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma | unknown | N/A | 20 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Sep 29, 2020 | clinicaltrials |
| NCT04004637 | CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia | unknown | Phase 1 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04398953 | A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL) | unknown | Phase 2 | 102 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 11, 2020 | clinicaltrials |
| NCT04544059 | Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 87 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT04537442 | Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT04532268 | A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL | unknown | Early Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Aug 31, 2020 | clinicaltrials |
| NCT04486872 | An Exploratory Clinical Trial of Autologous Humanized Anti-cluster of Differentiation Antigen 19/20(CD19/CD20) Dual Specific CAR-T Cells Injection | unknown | Phase 1 | 18 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 26, 2020 | clinicaltrials |
| NCT04500431 | Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM | unknown | Phase 1 | 10 | Shanghai Tongji Hospital, Tongji University School of MedicineOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT04500561 | YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial | unknown | Phase 1 / Phase 2 | 28 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 5, 2020 | clinicaltrials |
| NCT04497688 | Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma | unknown | N/A | 104 | CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2020 | clinicaltrials |
| NCT04496011 | Effect of the Cycloergometer in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | N/A | 30 | Federal University of Health Science of Porto AlegreOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT03669445 | Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma(IFM2018-01) | unknown | Phase 2 | 45 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT03679351 | "FU-IFM2009" Database Post IFM/DFCI 2009 Study(DB-FU-IFM2009) | unknown | — | 675 | University Hospital, ToulouseOTHER | 1 | Jul 30, 2020 | clinicaltrials |
| NCT04490590 | A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma | unknown | Phase 4 | 30 | Mingzhi ZhangOTHER | 1 | Jul 29, 2020 | clinicaltrials |
| NCT03778619 | MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin | unknown | Phase 1 / Phase 2 | 9 | GC Cell CorporationINDUSTRY | 1 | Jul 28, 2020 | clinicaltrials |
| NCT04470141 | A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma | unknown | Phase 2 | 130 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 0 | Jul 14, 2020 | clinicaltrials |
| NCT04434833 | A Single-cell Transcriptome Study in Patients With Non-Hodgkin's Lymphoma | unknown | — | 150 | Ruijin HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04435743 | Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas | unknown | — | 1,000 | Ruijin HospitalOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT04324879 | A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL) | unknown | Phase 2 | 80 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT03363555 | SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma | unknown | Phase 2 | 97 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 18, 2020 | clinicaltrials |
| NCT04275583 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule | unknown | Phase 1 | 40 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 17, 2020 | clinicaltrials |
| NCT04425824 | Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 20 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04432402 | Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma | unknown | N/A | 124 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 16, 2020 | clinicaltrials |
| NCT03042247 | Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma | unknown | — | 120 | Marco PicardiOTHER | 1 | Jun 12, 2020 | clinicaltrials |
| NCT04407845 | Atrial Fibrillation in Patients Receiving Ibrutinib(FABRIC) | unknown | — | 60 | European Georges Pompidou HospitalOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04407858 | Cardiovascular Complications of Carfilzomib(ICARE) | unknown | — | 60 | European Georges Pompidou HospitalOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04423549 | Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma | unknown | — | 800 | Sun Yat-sen UniversityOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04120350 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty(REMLA) | unknown | Phase 1 / Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT04412174 | A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04412889 | A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM | unknown | Early Phase 1 | 18 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Jun 2, 2020 | clinicaltrials |
| NCT04405375 | GPED Regimen for Relapsed/Refractory or Advanced ENKTCL | unknown | Phase 2 | 29 | Beijing Tongren HospitalOTHER | 1 | May 28, 2020 | clinicaltrials |
| NCT04388735 | Multiple Myeloma (MM) Quality of Life (QOL) Study | unknown | — | 360 | Massachusetts General HospitalOTHER | 1 | May 14, 2020 | clinicaltrials |
| NCT04040491 | PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | unknown | Phase 4 | 100 | Mingzhi ZhangOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT04370405 | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma | unknown | Phase 2 | 123 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 1 | May 11, 2020 | clinicaltrials |
| NCT04279379 | Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT04379167 | A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Follicular Lymphoma | unknown | Phase 2 | 140 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | May 7, 2020 | clinicaltrials |
| NCT04376957 | Pilot Study of an Oral Chemotherapy Teaching Tool to Improve Adherence in Patients With Multiple Myeloma | unknown | N/A | 60 | Hamilton Health Sciences CorporationOTHER | 0 | May 6, 2020 | clinicaltrials |
| NCT04364724 | CTFEA Myeloma Study | unknown | — | 200 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 0 | Apr 28, 2020 | clinicaltrials |
| NCT04338282 | Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 0 | Apr 8, 2020 | clinicaltrials |
| NCT04337593 | Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 0 | Apr 7, 2020 | clinicaltrials |
| NCT04337606 | Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | unknown | Phase 1 / Phase 2 | 100 | Chinese PLA General HospitalOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02733380 | Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 1, 2020 | clinicaltrials |
| NCT03260231 | Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma(Lymphoseed) | unknown | N/A | 40 | University of BelgradeOTHER | 1 | Mar 20, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Oct 14, 2020source: clinicaltrials